Table 1.
Adenosine use in Europe
| Total cases | Adenosine | ||
|---|---|---|---|
| Total (% of total within country) | % of total within Europe | ||
| Spain | 526 | 101 (19.2) | 27.5 |
| Netherlands | 242 | 41 (16.9) | 11.2 |
| Italy | 314 | 37 (11.8) | 10.1 |
| Austria | 41 | 27 (65.9) | 7.4 |
| United Kingdom | 48 | 22 (45.8) | 6.0 |
| Russian Federation | 467 | 21 (4.5) | 5.7 |
| Belgium | 84 | 20 (23.8) | 5.5 |
| Sweden | 108 | 14 (13.0) | 3.8 |
| Ukraine | 87 | 13 (14.9) | 3.5 |
| Finland | 170 | 13 (7.7) | 3.5 |
| Czech Republic | 79 | 11 (13.9) | 3.0 |
| Greece | 139 | 9 (6.5) | 2.5 |
| Ireland | 28 | 8 (28.6) | 2.2 |
| Portugal | 44 | 7 (15.9) | 1.9 |
| Poland | 338 | 7 (2.1) | 1.9 |
| Hungary | 60 | 5 (8.3) | 1.4 |
| Egypt | 78 | 5 (6.4) | 1.4 |
| France | 152 | 3 (2.0) | 0.8 |
| Germany | 204 | 2 (1.0) | 0.5 |
| Belarus | 20 | 1 (5.0) | 0.3 |
| Bulgaria | 107 | 0 (0.0) | 0.0 |
| Denmark | 17 | 0 (0.0) | 0.0 |
| Israel | 53 | 0 (0.0) | 0.0 |
| Kazakhstan | 30 | 0 (0.0) | 0.0 |
| Latvia | 35 | 0 (0.0) | 0.0 |
| Romania | 61 | 0 (0.0) | 0.0 |
| Slovenia | 66 | 0 (0.0) | 0.0 |